Investors

The worldwide cannabis market – recreational and medicinal – is expected to reach $140 billion by 2020 according to current industry reports. Cannabis is now legal or decriminalised in 44 countries worldwide, with more countries expected to follow.

Medicinal cannabis has the potential to replace up to 20% of the world’s medicinal market.

HERBA was established to provide Australian medical professionals, hospitals and patients access to a high-quality regulated supply of pharmaceutical grade cannabis as raw extracts and also as registered medicines.

HERBA is part of the Medropharm / Greenfields group of companies and is a full provider of an end-to-end cannabis solution from farming to extracts and formulations to pharmaceutical GMP products.

Medropharm / Greenfields is considered to be one of the global market leaders in high-quality phytopharmaceutical cannabis raw extracts with an existing medical product line, proprietary genetics, high-end Swiss cultivation and production facilities and secure distribution partnerships with pharmaceutical companies worldwide.

HERBA´s goal is to be one of the leading pharmaceutical cannabis companies in Australia with co-developments to register medicine for sale worldwide. The first drugs to be registered will be for the treatment of Epilepsy and Neuropathic Pain.

Our revenue streams

Sales

SALES

Sales of existing medicinal cannabis product line directly to medical professionals, hospitals, pharmacies and patients via the Special Access Schemes (SAS).

Registration

REGISTRATION

Registration of new cannabis-based medicines in Australia to directly treat pain, anti-inflammatory, and neurological diseases.

Growth

GROWTH

Growing and selling 2 tons of our proprietary CBD genetic M-1337 into the global wholesale market. Cultivated in 23,000sqm of prime greenhouse facilities.

Sales

SALES

Sales of existing medicinal cannabis product line directly to medical professionals, hospitals and pharmacies via pharmaceutical distribution.

Registration

REGISTRATION

Registration and sales of multiple cannabis medicines to address several multi-billion dollar industries including pain, anti-inflammatory, physiological and neuropathic diseases.

Growth

GROWTH

Growing and selling 2 tons of our proprietary CBD genetic M1337 into the global wholesale market. Cultivated in 23,000sqm of greenhouse facilities.

Our revenue streams

Sales

SALES

Sales of existing medicinal cannabis product line directly to medical professionals, hospitals and pharmacies via pharmaceutical distribution.

Registration

REGISTRATION

Registration and sales of multiple cannabis medicines to address several multi-billion dollar industries including pain, anti-inflammatory, physiological and neuropathic diseases.

Growth

GROWTH

Growing and selling 2 tons of our proprietary CBD genetic M1337 into the global wholesale market. Cultivated in 23,000sqm of greenhouse facilities.

Sales

SALES

Sales of existing medicinal cannabis product line directly to medical professionals, hospitals, pharmacies and patients via the Special Access Schemes (SAS).

Registration

REGISTRATION

Registration of new cannabis-based medicines in Australia to directly treat pain, anti-inflammatory, and neurological diseases.

Growth

GROWTH

Growing and selling 2 tons of our proprietary CBD genetic M-1337 into the global wholesale market. Cultivated in 23,000sqm of prime greenhouse facilities.

Worldwide, medical cannabis has seen a surge in popularity - with success in treating everything from pain, psychological disorders, inflammatory and neurological diseases. Interestingly cannabis-based medicine can work on its own or can be prescribed together with other medication (i.e. along with opioids), which may turn out to be a facilitator in the treatment.

HERBA positions itself as a purely medicinal company in contrast to the vast majority of other cannabis companies which blur the lines between recreational and medical cannabis by selling retail products, paraphernalia and other goods not associated with the healthcare industry.

Our approach is to develop evidence-based products through the realisation of clinical studies and their registration in some of the most significant markets in the world.

Herba has a limited number of spaces for investors to participate in our first and only round of fundraising. For more information, please use our contact form.